lgals3bpa Antibody

What is LGALS3BP and what is its significance in cancer research?

LGALS3BP is a highly glycosylated protein belonging to the galectin family of beta-galactoside-binding proteins that modulates cell-cell and cell-matrix interactions. It has been found elevated in the serum of patients with various cancers and those infected with HIV . Recent research indicates significant overexpression of LGALS3BP in oral squamous cell carcinoma (OSCC) and pancreatic ductal adenocarcinoma (PDAC), suggesting its potential as both a diagnostic biomarker and therapeutic target . LGALS3BP appears to be implicated in immune responses associated with natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity, making it a promising subject for immunotherapy research .

How is LGALS3BP expressed in different cancer types?

Expression patterns of LGALS3BP vary across cancer types but show consistent upregulation compared to normal tissues. In OSCC, LGALS3BP is highly expressed in the cytoplasm of tumor cells, with strong correlation between elevated expression levels and aggressive histological features . Proteomic analysis of pancreatic cancer identified LGALS3BP as a highly secreted protein in tumor interstitial fluid (TIF) but expressed at low levels in the pancreas under normal conditions . Immunohistochemical analysis of tissue microarrays containing PDAC (n=153) and matched normal tissues (n=21) validated significant overexpression of LGALS3BP in PDAC compared to normal tissue . The protein is also detectable in plasma samples, suggesting utility for liquid biopsy applications .

What are the optimal methods for detecting LGALS3BP in research samples?

Multiple complementary techniques should be employed for comprehensive LGALS3BP analysis:

For LGALS3BP detection in vesicular fractions, differential ultracentrifugation followed by Western blotting has been successfully employed in OSCC research . For plasma analysis, multiple reaction monitoring (MRM) mass spectrometry has demonstrated utility in distinguishing PDAC patient samples from controls .

How should researchers optimize Western Blotting protocols for LGALS3BP detection?

When conducting Western blotting for LGALS3BP, researchers should consider its predicted molecular weight of approximately 63 kDa, though observed weight may vary due to glycosylation patterns . For optimal results:

• Sample preparation should include appropriate protease inhibitors to prevent degradation.

• Purified antibodies supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose show good stability and performance .

• When using commercial antibodies, verify reactivity with human LGALS3BP and consider the immunogen regions (synthetic peptides directed towards the middle region of human LGALS3BP have shown good specificity) .

• Store antibodies at -20°C as received, where they typically remain stable for 12 months .

• Include positive controls from cells known to express LGALS3BP (such as OSCC or PDAC cell lines) to validate detection .

How can LGALS3BP serve as a therapeutic target in cancer?

LGALS3BP has demonstrated significant potential as a therapeutic target through several mechanisms:

• Antibody-Drug Conjugate (ADC) Therapy: LGALS3BP-expressing OSCC cell lines (HOC621 and CAL27) showed high sensitivity to the ADC-payload DM4, with an IC50 around 0.3 nM, suggesting efficacy for targeted therapy approaches .

• Antibody-Mediated Blockade: Development of antibody clones against LGALS3BP has profoundly abrogated metastasis of PDAC cells in vivo, demonstrating the potential of blocking antibodies as a therapeutic option for suppressing PDAC metastasis .

• Interruption of EGFR Signaling: LGALS3BP enhances galectin-3-mediated epidermal growth factor receptor signaling, leading to increased cMyc expression and epithelial-mesenchymal transition. Targeted inhibition could potentially disrupt this oncogenic pathway .

Research using knockdown models has consistently demonstrated that reduction of LGALS3BP expression attenuates cancer cell proliferation, migration, and invasion, further validating its potential as a therapeutic target .

What mechanisms underlie LGALS3BP's role in cancer progression and metastasis?

LGALS3BP contributes to cancer progression through multiple pathways:

• Cell Adhesion and Migration: LGALS3BP knockdown experiments in PDAC cells resulted in significantly suppressed cell adhesion, migration, and invasion capabilities, indicating its direct role in metastatic processes .

• Epithelial-Mesenchymal Transition (EMT): Reduction of LGALS3BP expression through siRNA transfection in PDAC cells led to decreased expression of EMT markers such as Zeb1, Claudin-1, and Snail. Conversely, overexpression of LGALS3BP in low-expressing PDAC cells resulted in upregulation of N-cadherin, Snail, and Zeb1 .

• EGFR Signaling Activation: LGALS3BP interacts with and enhances EGFR signaling in PDAC cells. Since EGFR is frequently upregulated and associated with poorer prognosis in PDAC, this interaction represents a significant mechanism of LGALS3BP's oncogenic effects .

• Extracellular Matrix Interactions: Beyond galectin-3, LGALS3BP can interact with galectin-1, β1‐integrins, and extracellular matrix proteins including collagen, fibronectin, and laminin, influencing tumor cell-stromal cell communication .

How can researchers address variability in LGALS3BP detection across experimental systems?

Variability in LGALS3BP detection may arise from several factors that researchers should systematically address:

• Glycosylation Heterogeneity: As a highly glycosylated protein, LGALS3BP may present different molecular weights and epitope accessibility depending on cell type and physiological conditions. Researchers should consider deglycosylation treatments prior to analysis to improve consistency .

• Subcellular Localization Variations: LGALS3BP exists in both intracellular and secreted forms, including enrichment in extracellular vesicles. Experimental protocols should clearly distinguish between these pools using appropriate fractionation techniques .

• Reference Standards: Establish consistent positive controls across experiments, potentially including recombinant LGALS3BP or lysates from high-expressing cell lines like HOC621 or CAL27 .

• Antibody Clone Validation: Different antibody clones may recognize distinct epitopes with varying accessibility. Cross-validation with multiple antibody clones can increase confidence in results .

• Quantification Methods: For precise quantification, combine multiple approaches (e.g., Western blot for relative expression, ELISA for absolute quantification) and ensure appropriate normalization strategies .

What considerations should guide experimental design for in vivo LGALS3BP functional studies?

In vivo studies investigating LGALS3BP function require careful experimental design:

• Model Selection: Both xenograft and syngeneic models have been successfully employed. Patient-derived xenograft (PDX) models provide closer recapitulation of human tumors, while syngeneic models (like PKCY cells in C57BL6 mice) allow for immune system interactions .

• Knockdown Validation: When using shRNA approaches to suppress LGALS3BP, multiple shRNA clones should be tested to confirm phenotypic consistency and rule out off-target effects. Studies have confirmed consistent results with multiple independent shRNA clones targeting LGALS3BP .

• Metastasis Assessment: Tail-vein injection models have demonstrated utility in assessing the impact of LGALS3BP manipulation on metastatic potential. Quantification should include lung weights, nodule counts, and histological confirmation .

• Growth vs. Migration Discrimination: To distinguish between effects on proliferation versus migration, consider pretreatment with low-dose mitomycin C (MMC) to halt cell growth before conducting migration assays .

• Therapeutic Antibody Evaluation: When testing blocking antibodies, consider both preventive (administration before tumor establishment) and therapeutic (administration after tumor establishment) protocols to assess different clinical scenarios .

What emerging applications of LGALS3BP antibodies warrant further investigation?

Several promising research directions for LGALS3BP antibodies include:

• Combination Therapies: Investigation of LGALS3BP-targeting antibodies in combination with conventional chemotherapies or immune checkpoint inhibitors could reveal synergistic therapeutic approaches .

• Liquid Biopsy Development: Given LGALS3BP's detectability in plasma samples, further development of sensitive and specific antibody-based detection methods could advance non-invasive diagnostic and monitoring approaches .

• Antibody-Drug Conjugate Optimization: Building on the promising sensitivity of LGALS3BP-expressing cells to ADC payloads, optimization of antibody-drug conjugate design specifically for LGALS3BP targeting represents an important avenue for translational research .

• Anti-Metastatic Preventive Therapy: The significant impact of LGALS3BP blockade on metastatic potential suggests potential applications in preventing metastasis in high-risk patients following primary tumor resection .

• Immune Response Modulation: Given LGALS3BP's implicated role in NK and LAK cell cytotoxicity, investigating how anti-LGALS3BP antibodies might modulate anti-tumor immune responses represents an underexplored area of research .